Company Overview - Rubico Inc. is a global provider of shipping transportation services, specializing in the ownership of vessels [5] - The company operates two modern, fuel-efficient, eco-friendly Suezmax tankers with a deadweight tonnage of 157,000 [5] - Rubico is incorporated under the laws of the Republic of the Marshall Islands and has its executive offices in Athens, Greece [5] Public Offering Details - Rubico announced a public offering of 6,666,666 units, each consisting of one share of common stock and 1.5 Class B Warrants, priced at $0.60 per unit [1] - The gross proceeds from the offering are expected to be approximately $4.0 million before deducting fees and expenses [2] - The offering is expected to close on or about January 12, 2026, subject to customary closing conditions [2] Securities Registration - A registration statement on Form F-1 was filed with the U.S. Securities and Exchange Commission (SEC) and became effective on January 9, 2026 [3] - A final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website [3]

As filed with the United States Securities and Exchange Commission on January 7, 2026. Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________________________ Willow Lane Acquisition Corp. II (Exact name of registrant as specified in its charter) _____________________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary St ...

Core Viewpoint - Investors are optimistic about a new public offering of Freddie Mac and the potential for its release from government conservatorship [1] Group 1 - The anticipation surrounding Freddie Mac's public offering indicates a growing confidence in the housing finance market [1] - The eventual release from government conservatorship is seen as a significant milestone for Freddie Mac, potentially unlocking value for investors [1]

Core Viewpoint - C3is Inc. has successfully closed a public offering, raising approximately $9 million to support its capital expenditures and general corporate purposes [1][3]. Offering Details - The offering consisted of 7,500,000 units, each including either one Common Share or one Pre-Funded Warrant, along with Class D and Class E Warrants [2]. - The public offering price was set at $1.20 per unit for Common Shares and $1.19999 per unit for Pre-Funded Warrants, with the Pre-Funded Warrants being immediately exercisable [2]. - Class D Warrants have an initial exercise price of $1.20 and are exercisable immediately, expiring 60 months after issuance [2]. - Class E Warrants have an exercise price of $0.00001 and are also immediately exercisable [2]. Use of Proceeds - The net proceeds from the offering will be utilized for capital expenditures, including the acquisition of additional vessels, working capital, and other general corporate purposes [3]. Company Overview - C3is Inc. is a ship-owning company that provides dry bulk and crude oil seaborne transportation services, owning four vessels with a total fleet capacity of 213,464 deadweight tons [6].

Core Points - C3is Inc. announced a public offering expected to generate approximately $9 million in gross proceeds before expenses [1][3] - The offering consists of 7,500,000 units, each including one Common Share or one Pre-Funded Warrant, along with Class D and Class E Warrants [2] - The transaction is anticipated to close on or about December 12, 2025, subject to customary closing conditions [3] Offering Details - Each unit in the offering is priced at $1.20 for a Common Share and $1.19999 for a Pre-Funded Warrant, with the Pre-Funded Warrants being immediately exercisable [2] - Class D Warrants have an initial exercise price of $1.20 per Common Share and are exercisable immediately, expiring 60 months after issuance [2] - Class E Warrants have an exercise price of $0.00001 per Common Share and are also immediately exercisable [2] Use of Proceeds - The net proceeds from the offering will be used for capital expenditures, including the acquisition of additional vessels, working capital, and other general corporate purposes [3] Company Overview - C3is Inc. is a ship-owning company that provides dry bulk and crude oil seaborne transportation services, owning four vessels with a total fleet capacity of 213,464 deadweight tons [6]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - ITT Inc. has announced a public offering of 7,000,000 shares of common stock at a price of $167.00 per share, with an additional option for underwriters to purchase up to 1,050,000 shares [1][2] Group 1: Offering Details - The estimated net proceeds from the offering are approximately $1.14 billion after deducting underwriting discounts and commissions, which will be used to fund a portion of the acquisition of SPX FLOW, Inc. [2] - The offering is expected to close on December 10, 2025, subject to customary closing conditions [1][2] - Goldman Sachs & Co. LLC and UBS Investment Bank are acting as lead book-running managers for the offering [3] Group 2: Regulatory Information - The offering is made pursuant to an automatic shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [4] - The preliminary prospectus supplement and accompanying base prospectus have been filed with the SEC and are available on the SEC's website [4] Group 3: Company Overview - ITT is a diversified manufacturer of critical components and customized technology solutions for transportation, industrial, and energy markets [6] - The company is headquartered in Stamford, Connecticut, and operates in over 35 countries with sales in approximately 125 countries [6]

Core Viewpoint - Structure Therapeutics Inc. has announced a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) to support its development of novel oral small molecule therapeutics for metabolic diseases, particularly obesity [1] Group 1: Offering Details - The company plans to grant underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants [2] - The offering is made under an automatic shelf registration statement on Form S-3, which was filed with the SEC on August 6, 2025 [4] Group 2: Management and Coordination - Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [3] Group 3: Company Overview - Structure Therapeutics is focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs, utilizing a next-generation structure-based drug discovery platform [6]

Core Viewpoint - Fulcrum Therapeutics, Inc. has initiated an underwritten public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million [1][2]. Group 1: Offering Details - The offering is being managed by J.P. Morgan, Leerink Partners, Cantor, Oppenheimer & Co., and Truist Securities [2]. - The shares are being offered under an effective shelf registration statement filed with the SEC on February 27, 2024, and declared effective on April 25, 2024 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3][5]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, including working capital, capital expenditures, research and development expenses, and potential acquisitions or investments [4]. Group 3: Company Overview - Fulcrum Therapeutics is focused on developing small molecules for patients with genetically defined rare diseases, with its lead program being pociredir for sickle cell disease [7]. - The company utilizes proprietary technology to identify drug targets that can modulate gene expression [7].

Core Viewpoint - Kestra Medical Technologies, Ltd. has announced an upsized underwritten public offering of 6,000,000 common shares priced at $23.00 per share, aiming for gross proceeds of $138 million before expenses [1]. Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage company focused on wearable medical devices and digital healthcare, specifically targeting improvements in patient outcomes for cardiovascular diseases through innovative monitoring and therapeutic technologies [6]. Offering Details - The offering is expected to close on December 4, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 900,000 common shares at the public offering price [1]. - The offering is being managed by BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities as bookrunners [2].